Skip to main content

Animations

MJFF Publications

3751 - 3760 of 8471 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    RESTRICTED
    Title: Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders
    Journal Name: CNS Drugs
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s40263-021-00796-y
    Best OA location URL:
    Citation Count: 8
  • Summary Details
    RESTRICTED
    Title: The role of immune-mediated alterations and disorders in ALS disease
    Journal Name: Human Immunology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.humimm.2021.01.017
    Citation Count: 19
  • Summary Details
    OPEN
    Title: The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-021-00162-1
    Citation Count: 17
  • Summary Details
    OPEN
    Title: TNF-α and α-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.celrep.2021.108895
    Citation Count: 47
  • Summary Details
    RESTRICTED
    Title: Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.01.005
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts?
    Journal Name: American Journal of Medical Quality
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1097/01.jmq.0000735440.58551.5b
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Challenges and Controversies in the Genetic Diagnosis of Hereditary Spastic Paraplegia
    Journal Name: Current Neurology and Neuroscience Reports
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s11910-021-01099-x
    Citation Count: 24
  • Summary Details
    OPEN
    Title: LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.02.018
    Citation Count: 19
  • Summary Details
    OPEN
    Title: LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awab073
    Citation Count: 24
  • Summary Details
    OPEN
    Title: No Evidence for a Causal Relationship Between Cancers and Parkinson’s Disease
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3233/jpd-202474
    Citation Count: 9
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.